Bioverativ Inc. (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively. ELOCTATE and ALPROLIX use a process known as Fc fusion to link recombinant factor VIII and factor IX, respectively, to a protein fragment in the body known as Fc. The fusion of the factor with the Fc protein fragment uses a naturally occurring pathway and is designed to extend the half-life of the factor thereby making the product last longer in a person's blood than various factor therapies. Its pipeline includes BIVV 001(rFVIIIFc-VWF-XTEN) and BIVV 002 (rFIXFc-XTEN).
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
Phone+1-781-6634400
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees460
OptionableNot Optionable
Bioverativ (NASDAQ:BIVV) Frequently Asked Questions
What is Bioverativ's stock symbol?
Bioverativ trades on the NASDAQ under the ticker symbol "BIVV."
How were Bioverativ's earnings last quarter?
Bioverativ Inc (NASDAQ:BIVV) issued its earnings results on Thursday, October, 26th. The biotechnology company reported $0.80 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.55 by $0.25. The biotechnology company earned $291.60 million during the quarter, compared to analysts' expectations of $285.45 million. The firm's revenue was up 27.2% compared to the same quarter last year. View Bioverativ's Earnings History.
What is the consensus analysts' recommendation for Bioverativ?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bioverativ in the last year. There are currently 7 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Bioverativ.
Has Bioverativ been receiving favorable news coverage?
Press coverage about BIVV stock has trended very positive on Tuesday, according to InfoTrie. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Bioverativ earned a coverage optimism score of 3.2 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
Who are Bioverativ's key executives?
Bioverativ's management team includes the folowing people:
- Brian S. Posner, Independent Chairman of the Board (Age 55)
- John G. Cox, Chief Executive Officer, Director (Age 54)
- John T. Greene, Chief Financial Officer, Executive Vice President, Treasurer (Age 51)
- Rogerio Vivaldi Coelho M.D., Executive Vice President, Chief Global Therapeutic Operations Officer (Age 53)
- Lucia Celona, Executive Vice President, Chief Human Resources and Corporate Communications Officer (Age 51)
- Richard Brudnick, Executive Vice President - Business Development (Age 60)
- Andrea Marie DiFabio, Executive Vice President, Chief Legal Officer (Age 48)
- Diantha Duvall, Vice President - Finance, Chief Accounting Officer (Age 45)
- Alexander J. Denner Ph.D., Independent Director (Age 47)
- Louis J. Paglia, Independent Director (Age 59)
How do I buy shares of Bioverativ?
Shares of BIVV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Bioverativ's stock price today?
One share of BIVV stock can currently be purchased for approximately $104.98.
What is Bioverativ's official website?
How can I contact Bioverativ?
Bioverativ's mailing address is 225 2nd Ave, WALTHAM, MA 02451-1122, United States. The biotechnology company can be reached via phone at +1-781-6634400 or via email at [email protected]
MarketBeat Community Rating for Bioverativ (NASDAQ BIVV)
MarketBeat's community ratings are surveys of what our community members think about Bioverativ and other stocks. Vote "Outperform" if you believe BIVV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIVV will underperform the S&P 500 over the long term. You may vote once every thirty days.
